801 related articles for article (PubMed ID: 15635112)
1. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Grinspoon S; Carr A
N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
[No Abstract] [Full Text] [Related]
2. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
Leclercq P; Blanc M
Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidaemia and cardiovascular risk in HIV infection.
Kulasekaram R; Peters BS; Wierzbicki AS
Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
Magen E; Elbirt D; Sthoeger Z
Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
[TBL] [Abstract][Full Text] [Related]
5. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of protease inhibitor therapy.
Bernasconi E
AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
[TBL] [Abstract][Full Text] [Related]
7. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
Fantoni M; Del Borgo C; Autore C; Barbaro G
Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
[TBL] [Abstract][Full Text] [Related]
8. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
[TBL] [Abstract][Full Text] [Related]
9. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Behrens GM
N Engl J Med; 2005 Apr; 352(16):1721-2; author reply 1721-2. PubMed ID: 15843678
[No Abstract] [Full Text] [Related]
11. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
12. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
14. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
16. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
Kolter DP
AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease and toxicities related to HIV infection and its therapies.
Zareba KM; Miller TL; Lipshultz SE
Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
[TBL] [Abstract][Full Text] [Related]
18. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.
Boccara F
AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
